-+ 0.00%
-+ 0.00%
-+ 0.00%

Silexion submits Germany trial application for SIL204 pancreatic cancer study

PUBT·04/28/2026 12:45:38
Listen to the news
Silexion submits Germany trial application for SIL204 pancreatic cancer study
  • Silexion submitted Phase 2/3 clinical trial application to Germany BfArM via EU CTIS for SIL204 in KRAS-driven locally advanced pancreatic cancer.
  • Germany will act as reporting member state for EU-wide scientific assessment under EU Clinical Trials Regulation.
  • Company still targets Phase 2/3 trial start in Q2 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604280845PRIMZONEFULLFEED1001178430) on April 28, 2026, and is solely responsible for the information contained therein.